Interaction Clinical Trial
Official title:
Pharmacokinetic Drug-Drug Interaction Study to Identify Biomarkers of Kidney Transporters
Verified date | August 2023 |
Source | Washington State University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The objective of this study is to confirm the feasibility of using a panel of endogenous substrates/metabolites as a robust biomarker of OCTs and OATs by conducting a controlled, comprehensive clinical drug-drug interaction study in healthy adult volunteers. Metformin and furosemide will be used as probe drugs for OCTs and OATs, respectively; cimetidine and probenecid will be used as corresponding inhibitors. Results from this study will validate this novel approach, which will be extended to children by collaborators at Children's Mercy Hospital in Kansas City, MO.
Status | Completed |
Enrollment | 32 |
Est. completion date | July 22, 2023 |
Est. primary completion date | July 22, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: Are from 18-65 years old and healthy - Are not taking any medications (prescription and non-prescription) or dietary/herbal supplements that can interfere with your ability to eliminate the study drugs from your body - Are willing to stop taking dietary/herbal supplements and citrus juices for several weeks - Are willing to stop consuming caffeinated beverages or other caffeine-containing products the evening before and the morning of the first day of each study arm - Are willing to stop drinking alcoholic beverages for at least 1 day prior to any study day and during the study day - Are willing to use an acceptable method of birth control that does not include oral contraceptive pills or patches (such as abstinence, copper IUD, condom) throughout your participation in the study and for at least 3 weeks after you last take the study drugs - Have the time to participate Exclusion Criteria: - Are under 18 or over 65 years old - Smoke/vape/chew tobacco products - Use cannabis products, including marijuana, hemp, and other THC- and CBDcontaining products• Are taking medications or dietary/herbal supplements that can interfere with your ability to eliminate the study drugs from your body - Have a chronic illness such as (but not limited to) kidney disease, liver disease, diabetes mellitus, high blood pressure, coronary artery disease, chronic obstructive pulmonary disease, cancer, or HIV/AIDS - Have a hematologic (blood) disorder - Have a history of drug or alcohol addiction or major psychiatric illness - Have a history of allergy to metformin, cimetidine, furosemide, or probenecid - Are pregnant, nursing, or plan to become pregnant within 3 weeks after participation |
Country | Name | City | State |
---|---|---|---|
United States | Washington State University College of Pharmacy and Pharmaceutical Sciences | Spokane | Washington |
Lead Sponsor | Collaborator |
---|---|
Washington State University | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH) |
United States,
Feng B, Varma MV. Evaluation and Quantitative Prediction of Renal Transporter-Mediated Drug-Drug Interactions. J Clin Pharmacol. 2016 Jul;56 Suppl 7:S110-21. doi: 10.1002/jcph.702. — View Citation
Miyake T, Mizuno T, Takehara I, Mochizuki T, Kimura M, Matsuki S, Irie S, Watanabe N, Kato Y, Ieiri I, Maeda K, Ando O, Kusuhara H. Elucidation of N 1-methyladenosine as a Potential Surrogate Biomarker for Drug Interaction Studies Involving Renal Organic Cation Transporters. Drug Metab Dispos. 2019 Nov;47(11):1270-1280. doi: 10.1124/dmd.119.087262. Epub 2019 Sep 11. — View Citation
Morrissey KM, Stocker SL, Wittwer MB, Xu L, Giacomini KM. Renal transporters in drug development. Annu Rev Pharmacol Toxicol. 2013;53:503-29. doi: 10.1146/annurev-pharmtox-011112-140317. Epub 2012 Nov 8. — View Citation
Naji-Talakar S, Sharma S, Martin LA, Barnhart D, Prasad B. Potential implications of DMET ontogeny on the disposition of commonly prescribed drugs in neonatal and pediatric intensive care units. Expert Opin Drug Metab Toxicol. 2021 Mar;17(3):273-289. doi: 10.1080/17425255.2021.1858051. Epub 2021 Jan 20. — View Citation
Shen H, Holenarsipur VK, Mariappan TT, Drexler DM, Cantone JL, Rajanna P, Singh Gautam S, Zhang Y, Gan J, Shipkova PA, Marathe P, Humphreys WG. Evidence for the Validity of Pyridoxic Acid (PDA) as a Plasma-Based Endogenous Probe for OAT1 and OAT3 Function in Healthy Subjects. J Pharmacol Exp Ther. 2019 Jan;368(1):136-145. doi: 10.1124/jpet.118.252643. Epub 2018 Oct 25. — View Citation
US Food and Drug Administration. Clinical Drug Interaction Studies - Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions Guidance for Industry. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-drug-interaction-studies-cytochrome-p450-enzyme-and-transporter-mediated-drug-interactions.
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Metformin area under the concentration vs. time curve (AUC) | baseline metformin AUC | 0-24 hours | |
Primary | Metformin area under the concentration vs. time curve (AUC) in presence of cimetidine | metformin AUC in the presence of cimetidine | 0-24 hours | |
Primary | Metformin maximum concentration (Cmax) | baseline metformin Cmax | 0-24 hours | |
Primary | Metformin maximum concentration (Cmax) in presence of cimetidine | metformin Cmax in the presence of cimetidine | 0-24 hours | |
Primary | Metformin renal clearance (CLr) | baseline metformin CLr | 0-24 hours | |
Primary | Metformin renal clearance (CLr) in presence of cimetidine | metformin CLr in the presence of cimetidine | 0-24 hours | |
Primary | Furosemide area under the concentration vs. time curve (AUC) | baseline furosemide AUC | 0-24 hours | |
Primary | Furosemide area under the concentration vs. time curve (AUC) in presence of probenecid | furosemide AUC in the presence of probenecid | 0-24 hours | |
Primary | Furosemide maximum concentration (Cmax) | baseline furosemide Cmax | 0-24 hours | |
Primary | Furosemide maximum concentration (Cmax) in presence of probenecid | furosemide Cmax in the presence of probenecid | 0-24 hours | |
Primary | Furosemide renal clearance (CLr) | baseline furosemide CLr | 0-24 hours | |
Primary | Furosemide renal clearance (CLr) in presence of probenecid | furosemide CLr in the presence of probenecid | 0-24 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02926326 -
The Effect of Azithromycin on BCT197 Exposure in Healthy Male Volunteers
|
Phase 1 | |
Completed |
NCT04257955 -
COMMUNIcation and Patient Engagement at Diagnosis of PAncreatic CAncer
|
||
Recruiting |
NCT04249674 -
Impact of CYP2D6 Genetic Polymorphisms on the Vulnerability to Drug-drug Interactions With Tramadol
|
||
Completed |
NCT01482117 -
The Effect of Genetic Polymorphism on Interactions of Clopidogrel and Cilostazol in Healthy Volunteers
|
N/A | |
Terminated |
NCT04842981 -
Interleukin-6 Inhibitors and Drug-drug Interactions in Patients With Rheumatoid Arthritis
|
Phase 1/Phase 2 | |
Completed |
NCT01447472 -
-Methylenedioxymethamphetamine (MDMA, Ecstasy) Induced Changes in Drug Metabolism: Gender and Genetic Polymorphisms
|
Phase 1 | |
Completed |
NCT03498170 -
The Effect of Itraconazole on BCT197 Exposure in Healthy Male Participants
|
Phase 1 | |
Recruiting |
NCT06053411 -
Contribution of UGT2B17 to the Pharmacokinetics of Diclofenac
|
Early Phase 1 | |
Completed |
NCT06411509 -
Integration of Tai Chi and Repetitive Transcranial Magnetic Stimulation for Sleep Disturbance in Older Adults
|
N/A | |
Active, not recruiting |
NCT05425303 -
System Dynamics Model for Acute Non-contact Lower Extremity Injuries Prediction
|
||
Completed |
NCT02067936 -
Walking the Isobole of Drug Interaction
|
N/A |